ICER to review treatments for tardive dyskinesia
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2017 Category: Drugs & Pharmacology Source Type: news
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Additional results from largest ever clinical program in tardive dyskinesia to be highlighted as platform and poster presentations
SAN DIEGO, April 21, 2017 -- (Healthcare Sales & Marketing Network) -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announ... Biopharmaceuticals, Neurology Neurocrine Biosciences, INGREZZA, valbenazine, tardive dyskinesia (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 21, 2017 Category: Pharmaceuticals Source Type: news
Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia
Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD). (Source: Drug Development Technology)
Source: Drug Development Technology - April 17, 2017 Category: Pharmaceuticals Source Type: news
FDA Approves First Drug for Treatment of Tardive Dyskinesia
Ingrezza (valbenazine) capsules approved for treatment of adults with tardive dyskinesia (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - April 13, 2017 Category: Psychiatry Tags: Family Medicine, Geriatrics, Internal Medicine, Neurology, Nursing, Pharmacy, Psychiatry, Institutional, Source Type: news
First Drug Approved for Tardive Dyskinesia (FREE)
By Amy Orciari Herman
Edited by Susan Sadoughi, MD, and Richard Saitz, MD, MPH, FACP, DFASAM
The FDA has approved valbenazine (Ingrezza) capsules to treat adults with tardive dyskinesia. The vesicular monoamine … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - April 13, 2017 Category: Primary Care Source Type: news
US FDA approves Neurocrine ’s Ingrezza capsules to treat tardive dyskinesia
The US Food and Drug Administration (FDA) has approved Neurocrine Biosciences ’ Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia (TD). (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - April 12, 2017 Category: Pharmaceuticals Source Type: news
1st Drug for Tardive Dyskinesia Approved
Condition characterized by involuntary movement of the jaw, lips and tongue
Source: HealthDay
Related MedlinePlus Pages: Medicines, Movement Disorders (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - April 12, 2017 Category: Consumer Health News Source Type: news
1st Drug for Tardive Dyskinesia, Ingrezza (Valbenazine), Approved
WEDNESDAY, April 12, 2017 -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.
The disorder is characterized by repetitive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2017 Category: Journals (General) Source Type: news
First Drug for Tardive Dyskinesia, Ingrezza (valbenazine), Approved
WEDNESDAY, April 12, 2017 -- Ingrezza (valbenazine), the first drug to treat adults with the neurological disorder tardive dyskinesia, has been approved by the U.S. Food and Drug Administration.
The disorder is characterized by repetitive... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 12, 2017 Category: Journals (General) Source Type: news
FDA approves first drug to treat tardive dyskinesia
The U.S. Food and Drug Administration approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. Tardive dyskinesia is a neurological disorder characterized by repetitive involuntary movements, usually of the jaw, lips and tongue, such as grimacing, sticking out the tongue and smacking the lips. (Source: World Pharma News)
Source: World Pharma News - April 12, 2017 Category: Pharmaceuticals Tags: Featured FDA Regulatory Affairs Source Type: news
FDA Approves Valbenazine (Ingrezza) for Tardive Dyskinesia FDA Approves Valbenazine (Ingrezza) for Tardive Dyskinesia
The US Food and Drug Administration has approved valbenazine, the first medication for the treatment of tardive dyskinesia.FDA Approvals (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - April 12, 2017 Category: Neurology Tags: Neurology & Neurosurgery News Alert Source Type: news
Neurocrine Biosciences gets FDA's OK for movement disorder drug
(Reuters) - The U.S. Food and Drug Administration approved Neurocrine Biosciences Inc's drug to treat tardive dyskinesia, a side effect of antipsychotic medications characterized by uncontrolled movements of the face and body, the company said. (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
FDA Okays First Tardive Dyskinesia Drug
(MedPage Today) -- VMAT2 inhibitor diminished abnormal involuntary movements in pivotal trial (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - April 11, 2017 Category: Psychiatry Source Type: news
FDA approves first drug to treat tardive dyskinesia
The U.S. Food and Drug Administration today approved Ingrezza (valbenazine) capsules to treat adults with tardive dyskinesia. This is the first drug approved by the FDA for this condition. (Source: Food and Drug Administration)
Source: Food and Drug Administration - April 11, 2017 Category: American Health Source Type: news
Neurocrine Announces FDA Approval of Ingrezza (valbenazine) as the First and Only Approved Treatment for Adults with Tardive Dyskinesia (TD)
SAN DIEGO, April 11, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that the U.S. Food and Drug Administration (FDA) has approved Ingrezza (valbenazine) capsules for the treatment of adults with tardive dyskinesia... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 11, 2017 Category: Drugs & Pharmacology Source Type: news
